Children’s Health Fund at the Catalytic Impact Foundation

Catalytic Impact Foundation’s Children’s Health Fund exists to accelerate discoveries for children with unmet medical needs. We invest catalytic philanthropy to unlock the full life-changing potential of biomedical research. Strategic investments today will improve lives for generations.

The need is clear. We must change the realities of childhood disease.

Children facing devastating medical needs deserve better, more tolerable treatments and cures. You can help bring these discoveries within reach.

Children’s mental health is in a state of crisis.

Imagine if your donation could help create a therapy that receives FDA approval and is available to children all around the world. And then what if your gift did that again, and again and again?

Your donation to Catalytic Impact Foundation becomes an investment in emerging life science companies, moving science closer to treatments.

When we are successful, our fund grows, our portfolio of investments grows, and more kids can access the cures and treatments they need to live healthier, longer lives. We are grateful for your support.

Children’s Health Fund Advisory Board

Our advisors contribute broad expertise and leadership in science, medicine, investing,
entrepreneurship, and philanthropy.

  • Michael Jensen, MD

    VP, Chief Therapeutics Officer, Seattle Children’s​

    ED, Seattle Children’s Therapeutics​

    Co-Founder, Juno Therapeutics

    ED, CureWorks​

  • Sam Blackman, MD, PhD

    Founder and CMO,
    Day One Biopharmaceuticals​

    Head of Clinical Development, Mavupharma, Inc

    Senior Medical Director,
    Juno Therapeutics

  • ​Derrell Porter, MD, MBA

    Founder and CEO, Cellevolve

    Global Head of Commercial,
    Altara Biotherapeutics, Inc

    VP and Head, Commercial Planning & Strategy, Gilead Sciences

  • ​Julie Park, MD

    Chair, Department of Oncology at St Jude’s Children’s Research Hospital

    Scientific Lead, New Approaches to Neuroblastoma Therapy (NANT) consortium

    Past Chair, Children’s Oncology Group Neuroblastoma Scientific Committee

  • ​Akira Matsuno

    Co-Founder, President & CFO,
    Tune Therapeutics

    Analyst, Investment Banking,
    Lehman Brothers

    CFO & Head of Corporate Developoment,
    Lyell Immunopharma

  • Patrick J Schwarz, CFP

    Managing Director,
    Private Wealth Advisor at
    Morgan Stanley Private Wealth Management